Here is the design of a clinical trial:

Official Title: Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients

Included conditions:
- SARS-CoV 2
- COVID-19

Study Armgroups:
- {'label': 'hydroxychloroquine', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Hydroxychloroquine']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Other: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Hydroxychloroquine', 'description': 'dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days', 'armGroupLabels': ['hydroxychloroquine']}
- {'type': 'OTHER', 'name': 'Placebo', 'description': 'Placebo: Film Coated Tablette', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': '● Rate of hospitalization or death at day 7 after study inclusion', 'timeFrame': '7 days'}

Please estimate the sample size based on the assumption: 
10% dropout rate is assumed.
Numbers to be randomised (sample size)
          In the first stage of an adaptive design 120 patients in a 2:1 ration: 72 Verum and 36 Placebo, plus an increase for 10% drop outs. After interim analysis, the total sample size will be calculated based on the effect seen in the first stage. Total sample size is estimated approximately n = 300-400 patients.